Shin Hatou, M.D., Ph.D., CEO 

Tokyo, Japan 


Virtual Presentation 

Cellusion is a regenerative medicine startup founded by three professors in Keio University’s School of Medicine, Department of Ophthalmology in Japan. Cellusion has several unique technologies including a highly efficient direct differentiation induction method to produce corneal endothelial substituted cells from iPS cells. The company’s lead program, CLS001 targeting Bullous Keratopathy, starts a first-in-human clinical study at Keio University Hospital soon. Additionally, the company has several pipelines focusing on not only ophthalmologic diseases, but also beyond. 



By using this website you agree to accept our Privacy Policy and Terms & Conditions